Clinical Trial Update: A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) [Phase 1]

View source ↗

Summary

Phase 1 trial update for dalotuzumab (MK-0646) in breast cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalotuzumab (dalotuzumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2017-04-14